Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Soluble fms-like tyrosine kinase-1 (sFlt-1), also known as soluble vascular endothelial growth factor receptor 1 (sVEGFR-1), is a truncated splice variant of the VEGF receptor Flt-1. It acts as a decoy receptor with antiangiogenic properties by binding and sequestering angiogenic factors such as vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), thereby reducing their bioavailability and inhibiting blood vessel formation. Elevated levels are associated with preeclampsia and chronic kidney disease.
Binds and sequesters VEGF and PlGF, preventing them from binding to their cell-surface receptors and inhibiting downstream signaling pathways involved in angiogenesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Soluble fms-like tyrosine kinase 1 (sFlt-1).